Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Iohexol
Drug ID BADD_D01180
Description Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.
Indications and Usage Iohexol ia used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures.
Marketing Status approved
ATC Code V08AB02
DrugBank ID DB01362
KEGG ID D01817
MeSH ID D007472
PubChem ID 3730
TTD Drug ID D02BLO
NDC Product Code 43228-100; 0407-1413; 71806-141; 0407-1414; 0407-1416; 0407-1415; 0407-1401; 0407-1411; 0407-1412; 65072-0801; 54702-501
UNII 4419T9MX03
Synonyms Iohexol | Iohexol 350 | Nycodenz | Compound 545 | Exypaque | Omnipaque
Chemical Information
Molecular Formula C19H26I3N3O9
CAS Registry Number 66108-95-0
SMILES CC(=O)N(CC(CO)O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dysacusis04.02.03.001---
Muscle tightness15.05.03.0070.014227%-
Anal sphincter atony07.03.01.003; 17.05.02.0090.007113%-
Idiosyncratic drug reaction08.06.01.002---
Ventricular hypokinesia02.04.02.013---
Skin tightness23.03.03.0180.026320%-
Acute coronary syndrome02.02.02.015; 24.04.04.0110.010670%-
Conjunctival hyperaemia06.04.01.0040.047660%-
Ear discomfort04.03.01.0050.026320%-
Ear pruritus04.03.01.0110.010670%-
Eye oedema06.08.03.0130.017783%-
Eye pruritus06.04.05.0060.303742%-
Nasal discomfort22.12.03.0120.010670%-
Oral pruritus07.05.05.0020.080381%-
Musculoskeletal stiffness15.03.05.027---
Musculoskeletal discomfort15.03.04.001---
Injection site swelling08.02.03.017; 12.07.03.0180.026320%-
Infusion site pain08.02.05.014; 12.07.05.0020.015649%-
Infusion site swelling08.02.05.002; 12.07.05.0030.015649%-
Type IV hypersensitivity reaction10.01.03.0220.007113%-
Skin burning sensation17.02.06.009; 23.03.03.0210.014227%-
Cerebral disorder17.02.10.0170.007113%-
Vulvovaginal pruritus21.08.02.004; 23.03.12.0090.019206%-
Temperature intolerance08.01.09.0220.021340%-
Hypoaesthesia oral07.05.05.003; 17.02.06.0210.061886%-
Paraesthesia oral07.05.05.035; 17.02.06.0080.197041%-
Toxic skin eruption10.01.01.008; 12.03.01.073; 23.03.05.0030.010670%-
Pulseless electrical activity02.03.04.0200.014227%-
Nuchal rigidity15.05.04.005; 17.05.02.0060.007113%-
Angiopathy24.03.02.007---
The 11th Page    First    Pre   11 12 13    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene